Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder

Mark Pollack, Gustavo Kinrys, Andrew Krystal, William Vaughn McCall, Thomas Roth, Kendyl Schaefer, Robert Rubens, James Roach, Holly Huang, Ranga Krishnan

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Context: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. Objective: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. Design: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study. Setting: Multicenter outpatient study from July 2005 to April 2006. Patients: Adults aged 18 to 64 years meeting DSMIV-TR criteria for GAD and insomnia. Interventions: Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n=294) or placebo (n=301) nightly for 8 weeks. For the last 2 weeks, eszopiclone was replaced with a single-blind placebo. Main Outcome Measures: Sleep, daytime functioning, psychiatric measures, and adverse events. Results: Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep and daytime functioning (P<.05), with no evidence of tolerance. Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton Anxiety Scale (HAM-A) scores at each week (P<.05) and at weeks 4 through 10 with the insomnia item removed. Clinical Global Impressions (CGI) of Improvement scores were improved with eszopiclone and escitalopram at every point (P<.02), while CGI of Severity of Illness scores were not significantly different after week 1. The HAM-A response (63% vs 49%, respectively, P=.001) and remission (42% vs 36%, respectively, P=.09) rates at week 8 were higher in patients treated with eszopiclone and escitalopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic response was significantly reduced (P≤.05). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and while treatment differences in anxiety measures were maintained, differences in sleep outcomes were not. Overall adverse event rates were 77.6% with cotherapy and 67.9% with monotherapy. The most common adverse events with cotherapy were unpleasant taste, headache, dry mouth, and somnolence. Conclusions: Coadministration of eszopiclone and escitalopram was well tolerated and associated with significantly improved sleep, daytime functioning, anxiety, and mood in patients with insomnia and GAD. Trial Registration: clinicaltrials.gov Identifier: NCT00235508.

Original languageEnglish (US)
Pages (from-to)551-562
Number of pages12
JournalArchives of General Psychiatry
Volume65
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Citalopram
Sleep Initiation and Maintenance Disorders
Anxiety Disorders
Placebos
Sleep
Anxiety
Eszopiclone
Placebo
Oxalates
Anti-Anxiety Agents
Therapeutics
Multicenter Studies
Headache
Psychiatry
Mouth
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. / Pollack, Mark; Kinrys, Gustavo; Krystal, Andrew; McCall, William Vaughn; Roth, Thomas; Schaefer, Kendyl; Rubens, Robert; Roach, James; Huang, Holly; Krishnan, Ranga.

In: Archives of General Psychiatry, Vol. 65, No. 5, 01.05.2008, p. 551-562.

Research output: Contribution to journalArticle

Pollack, M, Kinrys, G, Krystal, A, McCall, WV, Roth, T, Schaefer, K, Rubens, R, Roach, J, Huang, H & Krishnan, R 2008, 'Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder', Archives of General Psychiatry, vol. 65, no. 5, pp. 551-562. https://doi.org/10.1001/archpsyc.65.5.551
Pollack, Mark ; Kinrys, Gustavo ; Krystal, Andrew ; McCall, William Vaughn ; Roth, Thomas ; Schaefer, Kendyl ; Rubens, Robert ; Roach, James ; Huang, Holly ; Krishnan, Ranga. / Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. In: Archives of General Psychiatry. 2008 ; Vol. 65, No. 5. pp. 551-562.
@article{fde5a06a123046f1a0db40ad29926a44,
title = "Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder",
abstract = "Context: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. Objective: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. Design: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study. Setting: Multicenter outpatient study from July 2005 to April 2006. Patients: Adults aged 18 to 64 years meeting DSMIV-TR criteria for GAD and insomnia. Interventions: Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n=294) or placebo (n=301) nightly for 8 weeks. For the last 2 weeks, eszopiclone was replaced with a single-blind placebo. Main Outcome Measures: Sleep, daytime functioning, psychiatric measures, and adverse events. Results: Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep and daytime functioning (P<.05), with no evidence of tolerance. Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton Anxiety Scale (HAM-A) scores at each week (P<.05) and at weeks 4 through 10 with the insomnia item removed. Clinical Global Impressions (CGI) of Improvement scores were improved with eszopiclone and escitalopram at every point (P<.02), while CGI of Severity of Illness scores were not significantly different after week 1. The HAM-A response (63{\%} vs 49{\%}, respectively, P=.001) and remission (42{\%} vs 36{\%}, respectively, P=.09) rates at week 8 were higher in patients treated with eszopiclone and escitalopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic response was significantly reduced (P≤.05). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and while treatment differences in anxiety measures were maintained, differences in sleep outcomes were not. Overall adverse event rates were 77.6{\%} with cotherapy and 67.9{\%} with monotherapy. The most common adverse events with cotherapy were unpleasant taste, headache, dry mouth, and somnolence. Conclusions: Coadministration of eszopiclone and escitalopram was well tolerated and associated with significantly improved sleep, daytime functioning, anxiety, and mood in patients with insomnia and GAD. Trial Registration: clinicaltrials.gov Identifier: NCT00235508.",
author = "Mark Pollack and Gustavo Kinrys and Andrew Krystal and McCall, {William Vaughn} and Thomas Roth and Kendyl Schaefer and Robert Rubens and James Roach and Holly Huang and Ranga Krishnan",
year = "2008",
month = "5",
day = "1",
doi = "10.1001/archpsyc.65.5.551",
language = "English (US)",
volume = "65",
pages = "551--562",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder

AU - Pollack, Mark

AU - Kinrys, Gustavo

AU - Krystal, Andrew

AU - McCall, William Vaughn

AU - Roth, Thomas

AU - Schaefer, Kendyl

AU - Rubens, Robert

AU - Roach, James

AU - Huang, Holly

AU - Krishnan, Ranga

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Context: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. Objective: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. Design: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study. Setting: Multicenter outpatient study from July 2005 to April 2006. Patients: Adults aged 18 to 64 years meeting DSMIV-TR criteria for GAD and insomnia. Interventions: Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n=294) or placebo (n=301) nightly for 8 weeks. For the last 2 weeks, eszopiclone was replaced with a single-blind placebo. Main Outcome Measures: Sleep, daytime functioning, psychiatric measures, and adverse events. Results: Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep and daytime functioning (P<.05), with no evidence of tolerance. Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton Anxiety Scale (HAM-A) scores at each week (P<.05) and at weeks 4 through 10 with the insomnia item removed. Clinical Global Impressions (CGI) of Improvement scores were improved with eszopiclone and escitalopram at every point (P<.02), while CGI of Severity of Illness scores were not significantly different after week 1. The HAM-A response (63% vs 49%, respectively, P=.001) and remission (42% vs 36%, respectively, P=.09) rates at week 8 were higher in patients treated with eszopiclone and escitalopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic response was significantly reduced (P≤.05). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and while treatment differences in anxiety measures were maintained, differences in sleep outcomes were not. Overall adverse event rates were 77.6% with cotherapy and 67.9% with monotherapy. The most common adverse events with cotherapy were unpleasant taste, headache, dry mouth, and somnolence. Conclusions: Coadministration of eszopiclone and escitalopram was well tolerated and associated with significantly improved sleep, daytime functioning, anxiety, and mood in patients with insomnia and GAD. Trial Registration: clinicaltrials.gov Identifier: NCT00235508.

AB - Context: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. Objective: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. Design: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study. Setting: Multicenter outpatient study from July 2005 to April 2006. Patients: Adults aged 18 to 64 years meeting DSMIV-TR criteria for GAD and insomnia. Interventions: Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n=294) or placebo (n=301) nightly for 8 weeks. For the last 2 weeks, eszopiclone was replaced with a single-blind placebo. Main Outcome Measures: Sleep, daytime functioning, psychiatric measures, and adverse events. Results: Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep and daytime functioning (P<.05), with no evidence of tolerance. Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton Anxiety Scale (HAM-A) scores at each week (P<.05) and at weeks 4 through 10 with the insomnia item removed. Clinical Global Impressions (CGI) of Improvement scores were improved with eszopiclone and escitalopram at every point (P<.02), while CGI of Severity of Illness scores were not significantly different after week 1. The HAM-A response (63% vs 49%, respectively, P=.001) and remission (42% vs 36%, respectively, P=.09) rates at week 8 were higher in patients treated with eszopiclone and escitalopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic response was significantly reduced (P≤.05). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and while treatment differences in anxiety measures were maintained, differences in sleep outcomes were not. Overall adverse event rates were 77.6% with cotherapy and 67.9% with monotherapy. The most common adverse events with cotherapy were unpleasant taste, headache, dry mouth, and somnolence. Conclusions: Coadministration of eszopiclone and escitalopram was well tolerated and associated with significantly improved sleep, daytime functioning, anxiety, and mood in patients with insomnia and GAD. Trial Registration: clinicaltrials.gov Identifier: NCT00235508.

UR - http://www.scopus.com/inward/record.url?scp=43149106481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149106481&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.65.5.551

DO - 10.1001/archpsyc.65.5.551

M3 - Article

C2 - 18458207

AN - SCOPUS:43149106481

VL - 65

SP - 551

EP - 562

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 5

ER -